Prestige Consumer Healthcare (NYSE:PBH) Downgraded by StockNews.com to Hold

StockNews.com lowered shares of Prestige Consumer Healthcare (NYSE:PBH) from a buy rating to a hold rating in a report published on Thursday.

PBH has been the subject of a number of other research reports. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Finally, DA Davidson reiterated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $85.25.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $78.31 on Thursday. The business’s fifty day moving average is $80.56 and its two-hundred day moving average is $74.41. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The firm has a market cap of $3.87 billion, a P/E ratio of 19.05, a P/E/G ratio of 2.08 and a beta of 0.51. Prestige Consumer Healthcare has a 52 week low of $58.22 and a 52 week high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. The business had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.07 EPS. Equities research analysts forecast that Prestige Consumer Healthcare will post 4.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider William P’pool sold 8,987 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 over the last three months. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in PBH. Quest Partners LLC raised its stake in Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after buying an additional 424 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after acquiring an additional 433 shares in the last quarter. nVerses Capital LLC raised its position in shares of Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the period. Huntington National Bank lifted its holdings in shares of Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares in the last quarter. Finally, International Assets Investment Management LLC grew its position in shares of Prestige Consumer Healthcare by 7,112.5% in the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after purchasing an additional 1,138 shares during the period. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.